Selected HighlightsThird quarter Operating EBITDA* of negative $28.1 million (net loss of $80.8 million), including a non-cash inventory impairment of $20.4 million, compared to positive $50.5 million (net loss of $17.6 million) in the same quarter of 2024 Combined industry wide challenges stemming from the global economic and trade environment, higher fiber costs and pulp grade substitution intensified in the third quarter of 2025 Continued execution of our “One Goal One Hundred” program, targeting $100 million in cost savings and operational efficiency actions by the end of 2026 and taking additional steps aimed at improving liquidity through further cost reductions, lowering capital expenditures in 2026 and other working capital measuresNEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) — Mercer International Inc. (Nasdaq:...

Dallas, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) — Valhi, Inc. (NYSE: VHI) reported a net loss attributable to Valhi stockholders of $22.2 million, or $.78 per share, in the third quarter of 2025 compared to net income of $57.5 million, or $2.01 per share, in the third quarter of 2024. For the first nine months of 2025, Valhi reported a net loss attributable to Valhi stockholders of $4.4 million, or $.15 per share, compared to net income of $85.2 million, or $2.99 per share, in the first nine months of 2024. Net income attributable to Valhi stockholders decreased in the third quarter and first nine months of 2025 as compared to the same periods in 2024 primarily due to lower operating results from the Chemicals Segment, a third quarter non-cash gain in 2024 related to the Chemicals Segment acquisition of the 50% joint venture interest...

Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the third quarter ended September 30, 2025. The company also provided a business update that includes signing a $37.8m Supply Assurance Agreement with Merck and organizational changes, together will allow the company to extend its cash runway through 2027. “We’ve had a very exciting and important few months that have set us up very well for the changes we are announcing today” said Stephen Dilly, MBBS, PhD, CEO and Chairman at...

Dallas, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) — NL Industries, Inc. (NYSE: NL) today reported a net loss attributable to NL stockholders of $7.8 million, or $.16 per share, in the third quarter of 2025 compared to net income attributable to NL stockholders of $36.0 million, or $.74 per share, in the third quarter of 2024. NL results include an unrealized loss of $.5 million in the third quarter of 2025 related to the change in value of marketable equity securities compared to an unrealized gain of $18.6 million in the third quarter of 2024. For the first nine months of 2025, NL reported a net loss attributable to NL stockholders of $6.8 million, or $.14 per share, compared to net income attributable to NL stockholders of $50.7 million, or $1.04 per share, for the first nine months of 2024. NL results include an unrealized loss...

Steady Recurring Revenue* Growth and Adjusted EBITDA Margin* Expansion  TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) — Altus Group Limited (ʺAltus Group” or “the Company”) (TSX: AIF), a leading provider of commercial real estate (“CRE”) intelligence, announced today its financial and operating results for the third quarter ended September 30, 2025. Selected Q3 2025 InformationC$M Q3 2025 Q3 2024 % Change % Change CurrencyRevenue $133.3 $128.4 2.2%            Constant Currency*Recurring Revenue* $102.4 $95.4 5.2%          Constant CurrencyProfit (Loss) from continuing operations $0.5 $(2.9) 117.8% As ReportedAdjusted EBITDA* $25.6 $21.6 16.1%     Constant CurrencyAdjusted EBITDA margin* 19.2% 16.8% 230 bps    Constant CurrencyAnalytics Adjusted EBITDA margin* 32.8% 30.3% 250 bps    Constant CurrencyNet cash provided...

Quarterly revenue of $634 million and adjusted EBITDA of $58 million; GAAP income of $0.76/share and adjusted EPS of $0.39 DALLAS, Nov. 06, 2025 (GLOBE NEWSWIRE) — AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its third quarter 2025 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q3 2025 % Change Q3 2024 YTD September 30, 2025 % Change YTD September 30, 2024Revenue $634.5 (8%) $1,982.2 (12%)Gross profit $184.4 (13%) $578.9 (17%)Net income (loss) $29.3 319% $(88.0) nmDiluted income (loss) per share $0.76 322% $(2.29) nmAdjusted diluted EPS* $0.39 (36%) $1.14 (55%)Adjusted EBITDA* $57.5 (22%) $180.0 (32%)* See “Non-GAAP Measures” below...

Updates Full Year 2025 Financial Guidance RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights:Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%.Software revenue was $43.8 million, compared to $35.9 million in the third quarter of 2024, representing growth of 22%. Services revenue was $60.8 million, compared to $58.9 million in the third quarter of 2024, representing growth of 3%.Net income was $1.5 million, compared to a net loss of $1.4 million in the third quarter of 2024, representing growth of 211%. Adjusted EBITDA was $35.2 million, compared to $33.1 million in the third quarter...

Gross margin decreased 400 basis points year-over-year to 39.7%Reported net loss of $4 million, adjusted EBITDA1 of $1.4 millionNet sales of $81.6 million FORT WORTH, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) — Farmer Brothers Coffee Co. (NASDAQ: FARM), a leading roaster, wholesaler and distributor of coffee, tea and allied products, announced today its first quarter fiscal 2026 financial results for the period ended Sept. 30, 2025. The company filed its Form 10-Q, which will be posted on the Investor Relations section of its website after the close of market on Thursday, Nov. 6. “Fiscal 2025 was a year of significant operational and financial improvement for Farmer Brothers. I am very pleased we were able to maintain the majority of that progress despite a very challenging economic environment during the first quarter,” said President...

Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026  $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041 HIGH POINT, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the third quarter ended September 30, 2025, and provided an update on recent corporate developments. “The third quarter saw a series of meaningful achievements,” said Paul...

Dallas, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) — November 6, 2025…Kronos Worldwide, Inc. (NYSE:KRO) today reported a net loss of $37.0 million, or $.32 per share, in the third quarter of 2025 compared to net income of $71.8 million, or $.62 per share, in the third quarter of 2024. For the first nine months of 2025, Kronos Worldwide reported a net loss of $28.1 million, or $.24 per share, compared to net income of $99.4 million, or $.86 per share, in the first nine months of 2024. Net loss increased in the third quarter and first nine months of 2025 due to legislation enacted in Germany during the third quarter of 2025, which included a reduction of the corporate tax rate from 15% by one percentage point annually for five years, reaching 10% in 2032. As a result, we recorded a non-cash deferred income tax expense of $19.3 million...